Physician profile
Fernando E Ottino
NPI 1326224569
$1,929.84
in general payments reported to CMS, 2019-2025
8 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $207 · 2021: $249 · 2022: $243 · 2023: $256 · 2024: $385 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.59 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $758.66 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Akebia Therapeutics INC | $732.54 | 2019-2024 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $161.62 | 2022-2025 | |
| Amgen INC. | $91.53 | 2019-2022 | |
| Ardelyx, INC. | $90.53 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $46.87 | 2021-2024 | Farxiga |
| Mallinckrodt Enterprises LLC | $32.85 | 2019 | |
| Calliditas Therapeutics US INC. | $15.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Ottino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.